Cure - Investment

Ten firms writing checks into women's health in 2026, from menopause and cardiovascular care to bone density, autoimmune disease, and oncology.

From early-stage senolytics to AI-driven drug discovery, these seven firms are actively writing checks in longevity biotech.

Success factors go beyond funding, publications and patents to identify the top 303 U.S. Research Institutions making real-world impact

Brianne Kimmel is redefining how women’s health gets funded. As founder and managing partner of WorkLife Ventures, she invests in female-led startups focused on making care more accessible, affordable, and aligned with women’s real-life needs.

A practical guide for biotech founders on how to navigate the investor Q&A with clarity and confidence. Learn how to prepare, show traction, communicate your why, and present a plan investors can trust.

Accelerator director Dr. Mussaad M. Al-Razouki shares how the Cure by Deerfield Middle East Health Accelerator in Qatar can serve as a launchpad for trailblazing life sciences startups.

Milestone-based financing can be an effective way for investors to manage risk and for founders to complete successful clinical trials and gain regulatory approval. Here's what biotech entrepreneurs need to know before seeking this type of funding.

Whether pitching to angels, applying to accelerators, or negotiating venture capital, knowing the right funding terms can make or break your credibility as a healthcare founder. This guide breaks down the must-know concepts to help you speak the language of investors and secure the capital you need to grow.

After decades of little change, a record number of late-stage clinical trials is reshaping the landscape of allergy medicine.

As pharmaceutical giants pour billions into new U.S. labs and factories, demand rises for equipment suppliers and workforce training.

Global Healthcare Startups Invited to Apply for 12-Week Program with Mentorship, Investor Exposure, and Pitch Competition New York, Sept. 18, 2025 — Cure, a premier healthcare innovation ecosystem headquartered in New York City, today announced the launch of the Cure by Deerfield Middle East Health Accelerator, which is now accepting applications for its first cohort of healthcare startup founder…

Experts advise focusing on three main factors that can help founders refine their message, highlight market fit, and ultimately secure funding.

More than one-third of all new life sciences lab construction in the U.S. is taking place outside the traditional power centers, ushering a new era of geographic growth.

From misaligned investor expectations to trial design pitfalls, healthcare entrepreneurs face obstacles on their road to growth. Experts from Rev1 Ventures and Vittoria Biotherapeutics share how to anticipate these challenges, and turn them into points of progress.

Intellectual property (IP) is often a startup’s most valuable asset. Patent litigator Anthony J. Fitzpatrick of Duane Morris LLP shares what healthcare entrepreneurs need to know about patents, trade secrets, and copyrights, plus common costly mistakes to avoid.

With more than $2.5 billion raised since 2019, BioLabs@NYULangone is giving healthcare entrepreneurs the tools, capital access, and collaborative ecosystem needed to accelerate innovation in life sciences.

At a time when federal funding is shrinking, healthcare startups are finding critical support from mission-driven venture philanthropies like the ADDF and LLS willing to back early-stage, high-risk science.

CEOs of Veravas, Persephone Bioscience, and Citius Pharmaceuticals reveal what it takes to helm your own startup, the mistakes that can derail you, and how to know when it’s time to step aside.

Crowdfunding can offer mission-driven healthcare startups early traction and autonomy, but founders must navigate investor perceptions, regulatory complexity, and platform tradeoffs.

The Gates Foundation’s $2.5 billion pledge is historic, but founders say it’s only a starting point. Here’s how they want the money to be spent, and why more bold action is still needed.